Patent number: 6777407
Abstract: This invention provides compounds of the formulae:
wherein:
R1 is hydrogen, —C(O)CH3 or alkyl of 1-6 carbon atoms;
R2 and R3 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, cycloalkyl, alkoxy of 1-6 carbon atoms, —CH2OH, fluoroalkyl, alkyl sulfonamide of 1-6 carbon atoms, alkyl amide of 1-6 carbon atoms, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl moiety, fluoroalkoxy of 1-6 carbon atoms, acyl of 2-7 carbon atoms, aryl, or aroyl;
R4 and R5 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, fluoroalkyl, —CN, alkyl sulfonamide of 1-6 carbon atoms, alkyl amide of 1-6 carbon atoms, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl moiety, fluoroalkoxy of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl;
R6 and R7 are each independently hydrogen, C1-C6 alkyl or cycloalkyl;
or a pharmaceutically acceptable salt thereof, as well as pharmaceut
Type:
Grant
Filed:
November 2, 2001
Date of Patent:
August 17, 2004
Assignee:
Wyeth
Inventors:
Annmarie Louise Sabb, Robert Lewis Vogel, James Albert Nelson, Sharon Joy Rosenzweig-Lipson, Gregory Scott Welmaker, Joan Eileen Sabalski
Patent number: 6706714
Abstract: This invention provides compounds of formula I,
R is hydrogen or alkyl of 1-6 carbon atoms;
R′ is hydrogen, alkyl of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl;
R1, R2, R3, and R4 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, trifluoroalkyl, —CN, alkyl sulfonamide of 1-6 carbon atoms, alkyl amide of 1-6 carbon atoms, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl moiety, trifluoroalkoxy of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl;
X is CR5R6 or a carbonyl group;
R5 and R6 are each, independently, hydrogen or alkyl of 1-6 carbon atoms;
or a pharmaceutically acceptable salt thereof, with the proviso that at least one of R1, R2, R3, or R4 are not hydrogen;
which are 5HT2C receptor agonists useful for the treatment of disorders involving the central nervous system such as obsessive-compulsive disorder, depression, anxiety, schizophrenia, migraine, sleep disorders, eatin
Type:
Grant
Filed:
September 16, 2002
Date of Patent:
March 16, 2004
Inventors:
Annmarie Louise Sabb, Gregory Scott Welmaker, James Albert Nelson
Patent number: 6503900
Abstract: This invention provides [1,4]diazepino[6,7,1-jk]carbazole compounds of the formula:
wherein: R1 and R2 are H, alkyl, alkoxy, halogen, fluorinated alkyl, —CN, —NH—SO2-alkyl, —SO2—NH-alkyl, alkyl amide, amino, alkylamino, dialkylamino, fluorinated alkoxy, acyl, phenoyl or thiophenoyl; R3, R4, R5 and R6 are H, alkyl, cycloalkyl, alkoxy or cycloalkoxy; R7 is H or alkyl; R8 is H or alkyl; and the dashed line indicates an optional double bond; or a pharmaceutically acceptable salt thereof, as well as methods and pharmaceutical compositions utilizing them for the treatment or prevention of disorders such as obsessive-compulsive disorder, depression, anxiety, schizophrenia, migraine, sleep disorders, eating disorders, obesity, epilepsy, and spinal cord injury.
Type:
Grant
Filed:
November 2, 2001
Date of Patent:
January 7, 2003
Assignee:
Wyeth
Inventors:
Annmarie Louise Sabb, Gregory Scott Welmaker, Robert Lewis Vogel, Joan Eileen Sabalski
Patent number: 6476032
Abstract: This invention provides compounds of formula I,
wherein
R is hydrogen or alkyl of 1-6 carbon atoms;
R′ is hydrogen, alkyl of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl;
R1, R2, R3, and R4 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, halogen, trifluoroalkyl, —CN, alkyl sulfonamide of 1-6 carbon atoms, alkyl amide of 1-6 carbon atoms, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl moiety, trifluoroalkoxy of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or aroyl;
X is CR5R6 or a carbonyl group;
R5 and R6 are each, independently, hydrogen or alkyl of 1-6 carbon atoms;
or a pharmaceutically acceptable salt thereof, with the proviso that at least one of R1, R2, R3, or R4 are not hydrogen;
which are 5HT2C receptor agonists useful for the treatment of disorders involving the central nervous system such as obsessive-compulsive disorder, depression, anxiety, schizophrenia, migraine, sleep disorde
Type:
Grant
Filed:
June 26, 2001
Date of Patent:
November 5, 2002
Assignee:
Wyeth
Inventors:
Sharon Joy Rosenzweig-Lipson, Annmarie Louise Sabb, Gregory Scott Welmaker, James Albert Nelson
Patent number: 6414144
Abstract: The present invention provides processes for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b][1, 4]diazepino[6, 7, 1-hi]indole derivatives of the general formula:
wherein: R is H, alkyl, acyl, or aroyl; R1, R2, R4 and R5 are H, OH, alkyl, cycloalkyl, alkoxy s, halogen, fluorinated alkyl, —CN, —NH—SO2-alkyl, —SO2—NH-alkyl, alkyl amide, amino, alkylamino s, dialkylamino, fluorinated alkoxy, acyl, aryl, or aroyl; R3 is H, alkyl, cycloalkyl, alkoxy, fluorinated alkyl, —NH—SO2-alkyl, —SO2—NH-alkyl, alkyl amide, amino, alkylamino, dialkylamino, fluorinated alkoxy, acyl, aryl, or aroyl; or a pharmaceutically acceptable salt thereof, which are useful in the treatment of central nervous system disorders.
Type:
Grant
Filed:
November 2, 2001
Date of Patent:
July 2, 2002
Assignee:
Wyeth
Inventors:
Gregory Scott Welmaker, Joan Eileen Sabalski